AN2 Therapeutics, Inc. (ANTX) at Guggenheim 3rd Annual Healthcare Innovation Conference - AN2 THERAPEUTICS INC

Financial Performance:

• No specific financial figures (revenue, earnings, cash flow, debt, or profit margins) disclosed, as AN2 Therapeutics is a clinical-stage biopharmaceutical company with no commercial products generating revenue.
• The company's financial status relies on existing capital to fund clinical development; no guidance on cash burn or runway provided during the call.

Guidance and Future Outlook:

• Polycythemia Vera (PV): Plan to dose first patient in sentinel cohort by end of current year; initial safety readout expected in Q1 of next year; robust data sets anticipated around mid-year; multiple milestones and updates projected throughout 2027.
• Chagas Disease: Trial startup expected early 2027; enrollment expected to be rapid due to high prevalence in Bolivia; data readout projected for the second half of 2027.
• NTM (MAC): Focus on pivoting to Mycobacterium abscessus with earlier-stage, treatment-naive patients; timeline for this pivot not explicitly dated but prioritized based on superior potency data.
• Oncology: Timeline to advance pan-mutant PI3K inhibitor into development extends into next year; currently in research phase seeking strategic partners.

Business Segments and Product Lines:

• Polycythemia Vera (PV): Phase 2 trial design includes a 10-patient sentinel cohort, a 75-patient open-label Part 1, a randomized withdrawal Part 2, and a long-term extension. Aims to be the first oral therapy for PV.
• Chagas Disease: Phase 2 trial in Bolivia targeting 60 patients; utilizes a 2-dose regimen designed to achieve sterilization (cure) of parasites; eligible for Priority Review Voucher (PRV) under the Orphan Drug Act.
• NTM (Non-Tuberculous Mycobacteria): Shifting focus from Phase 3 MAC failure to Mycobacterium abscessus due to 250x higher potency; aims to replace off-label IV-only chemotherapy with an oral regimen.
• Oncology: Developing a boron-based pan-mutant PI3K inhibitor with unique binding chemistry designed to minimize hyperglycemia and maximize separation over wild-type kinases compared to competitors (e.g., Relay, Synovate/Novartis).
• Pipeline Expansion: Recently announced a new program for Hypophosphatasia entering development, with Phase 1 planned for next year.

Market and Competitive Landscape:

• PV: Competitors (e.g., Ruspertide) are injectables; AN2 aims to provide an oral alternative with efficacy comparable to or better than current benchmarks (60-70% hematocrit control).
• Chagas: Market size estimated at 10 million globally; US prevalence estimated at 300,000+ (likely underreported); no approved drugs for chronic adult Chagas exist.
• NTM: Current standard of care is long-term IV antibiotics (e.g., imipenem, amikacin); significant unmet need for oral therapies to improve patient quality of life.
• Oncology: Differentiating from "second-generation" agents by targeting a broader mutant profile with improved therapeutic index (lower toxicity), creating potential value for large breast cancer franchises.

Risks and Challenges:

• PV: Primary risk is translating observed red blood cell effects from non-PV populations to the specific PV patient population; safety and dose-response curves unknown in PV.
• MAC: Past Phase 3 failure in refractory MAC populations attributed to enrollment of patients with significantly higher disease burden and multi-drug resistance than the comparator drug's pivotal trial population.
• Clinical Execution: Enrollment rates in PV trials depend on site experience; data readout timelines contingent on patient recruitment speed.
• Competition: Oncology space is crowded with established players; must prove unique "more-on" chemistry provides a distinct clinical advantage over existing PI3K inhibitors.

Management Commentary and Tone:

• Tone: Highly confident and enthusiastic ("super excited," "bullish," "quasi-certain"), particularly regarding the Chagas program and the PV safety database.
• Strategy: Emphasizes "boron chemistry" platform versatility across diverse therapeutic areas (oncology, infectious disease, bone) and biology-driven selection rather than disease-area agnosticism.
• Risk Mitigation: Highlights extensive preclinical data (105+ patients in NTM, 10+ studies, NHP chronic tox) as a de-risking factor for the PV program, noting it is "unusual" for a Phase 2 asset.

Analyst Questions and Answers:

• Q: Trial Design Rationale for PV? A: Designed to first establish proof of concept and safety (sentinel/part 1), then confirm durability and reversibility (randomized withdrawal), with long-term extension planned.
• Q: Safety Database Depth? A: Leverages data from 105 patients over 12-15 months in NTM trials, plus preclinical NHP data and PK/PD modeling, providing a large safety dataset prior to PV dosing.
• Q: Mechanism of Action for PV? A: Targets late-stage erythropoiesis (globin synthesis), not bone marrow precursors; effects are predictable, monitorable, and reversible; no impact on iron stores.
• Q: Efficacy Thresholds? A: While no strict commercial target profile set, management expects efficacy at least comparable to injectable competitors (60-70% control), with room for oral advantage.
• Q: Confidence in Chagas Success? A: Extremely high; based on three successful NHP studies with naturally infected parasites and prior success of a boron-based drug (acoziboril) for African sleeping sickness.
• Q: Lessons from MAC Failure? A: Failure due to overly refractory patient population (9 years duration, multi-drug resistance) compared to the pivotal trial of competitor drugs; pivot to treatment-naive M. abscessus expected to yield success.
• Q: Oncology Differentiation? A: Focus on "more-on" chemistry providing superior separation over wild-type kinase and helicase, potentially avoiding hyperglycemia seen in other pan-kinase inhibitors.

Other Key Points:

• Geographic Focus: Chagas trial to be conducted in Bolivia due to the highest global prevalence rates; US blood supply screening used to estimate domestic market size.
• Orphan Drug Benefits: Chagas program is eligible for Priority Review Voucher (PRV) and Orphan Drug designation.
• Platform Versatility: AN2 demonstrates the ability to translate boron chemistry across distinct mechanisms (hematocrit control, trypanosome cure, bacterial cell wall synthesis inhibition, kinase inhibition).